NFE2L2 and cancer: Brusatol has been reported to sensitize cancer cells to carboplatin, 5-fluorouracil, gemcitabine, etoposide, and paclitaxel by regressing Nrf2-dependent anti-oxidant response pathway [4, 6, 21].